(SIGA) SIGA Technologies - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 312m USD | Total Return: -9.4% in 12m
Avg Turnover: 2.10M
Qual. Beats: 0
Rev. Trend: 25.4%
Warnings
Earnings expected to drop: P/E 15.6 → Forward 53.5
Extended 1w
Tailwinds
No distinct edge detected
SIGA Technologies, Inc. is a New York-based pharmaceutical firm specializing in health security and medical countermeasures. Its primary commercial product is TPOXX (tecovirimat), an antiviral medication developed for the treatment of human smallpox disease. The company operates within the niche biodefense sector, where revenue is frequently driven by long-term procurement contracts with federal agencies such as the Biomedical Advanced Research and Development Authority (BARDA).
The health security market focuses on addressing biological, chemical, and radiological threats, often relying on government stockpiling programs rather than traditional consumer prescription channels. For a deeper analysis of these government-linked revenue streams, investors should consult ValueRay. This business model provides a unique risk profile, as financial performance is closely tied to the renewal and expansion of national security defense contracts.
- U.S. government procurement contracts for TPOXX stockpiling drive core revenue
- Global mpox outbreaks trigger international orders and emergency use authorizations
- Expansion of TPOXX oral and intravenous labels impacts total addressable market
- Dependence on single-product portfolio creates significant concentration and regulatory risk
- BARDA funding cycles determine long-term cash flow and research development capacity
| Net Income: 20.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -12.55 > 1.0 |
| NWC/Revenue: 156.1% < 20% (prev 171.0%; Δ -14.98% < -1%) |
| CFO/TA 0.13 > 3% & CFO 27.7m > Net Income 20.3m |
| Net Debt (-144.3m) to EBITDA (21.2m): -6.81 < 3 |
| Current Ratio: 3.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.7m) vs 12m ago 0.31% < -2% |
| Gross Margin: 65.36% > 18% (prev 0.77%; Δ 6.46k% > 0.5%) |
| Asset Turnover: 40.21% > 50% (prev 48.70%; Δ -8.49% > 0%) |
| Interest Coverage Ratio: 3.09 > 6 (EBITDA TTM 21.2m / Interest Expense TTM 6.67m) |
| A: 0.67 (Total Current Assets 211.5m - Total Current Liabilities 65.2m) / Total Assets 219.4m |
| B: -0.41 (Retained Earnings -90.4m / Total Assets 219.4m) |
| C: 0.09 (EBIT TTM 20.6m / Avg Total Assets 233.2m) |
| D: -1.33 (Book Value of Equity -90.4m / Total Liabilities 67.8m) |
| Altman-Z'' = 2.23 = BBB |
| DSRI: 0.80 (Receivables 4.50m/7.19m, Revenue 93.8m/120.3m) |
| GMI: 1.17 (GM 65.36% / 76.55%) |
| AQI: 0.57 (AQ_t 0.03 / AQ_t-1 0.05) |
| SGI: 0.78 (Revenue 93.8m / 120.3m) |
| TATA: -0.03 (NI 20.3m - CFO 27.7m) / TA 219.4m) |
| Beneish M = -3.48 (Cap -4..+1) = AA |
As of May 23, 2026, the stock is trading at USD 4.71 with a total of 844,759 shares traded.
Over the past week, the price has changed by +12.23%,
over one month by +3.77%,
over three months by -21.16% and
over the past year by -9.41%.
SIGA Technologies has no consensus analysts rating.
| Analysts Target Price | 17.5 | 272.2% |
P/E Forward = 53.4759
P/S = 3.3309
P/B = 2.2754
P/EG = 3.3673
Revenue TTM = 93.8m USD
EBIT TTM = 20.6m USD
EBITDA TTM = 21.2m USD
Long Term Debt = 100k USD (estimated: total debt 638k - short term 538k)
Short Term Debt = 538k USD (from shortTermDebt, last quarter)
Debt = 1.23m USD (from shortLongTermDebtTotal, last quarter) + Leases 595k
Net Debt = -144.3m USD (calculated: Debt 1.23m - CCE 145.6m)
Enterprise Value = 168.0m USD (312.4m + Debt 1.23m - CCE 145.6m)
Interest Coverage Ratio = 3.09 (Ebit TTM 20.6m / Interest Expense TTM 6.67m)
EV/FCF = 6.13x (Enterprise Value 168.0m / FCF TTM 27.4m)
FCF Yield = 16.32% (FCF TTM 27.4m / Enterprise Value 168.0m)
FCF Margin = 29.23% (FCF TTM 27.4m / Revenue TTM 93.8m)
Net Margin = 21.61% (Net Income TTM 20.3m / Revenue TTM 93.8m)
Gross Margin = 65.36% ((Revenue TTM 93.8m - Cost of Revenue TTM 32.5m) / Revenue TTM)
Gross Margin QoQ = 52.89% (prev 21.33%)
Tobins Q-Ratio = 0.77 (Enterprise Value 168.0m / Total Assets 219.4m)
Interest Expense / Debt = 540.7% (Interest Expense 6.67m / Debt 1.23m)
Taxrate = 23.36% (7.10m / 30.4m)
NOPAT = 15.8m (EBIT 20.6m * (1 - 23.36%))
Current Ratio = 3.25 (Total Current Assets 211.5m / Total Current Liabilities 65.2m)
Debt / Equity = 0.01 (Debt 1.23m / totalStockholderEquity, last quarter 151.6m)
Debt / EBITDA = -6.81 (Net Debt -144.3m / EBITDA 21.2m)
Debt / FCF = -5.26 (Net Debt -144.3m / FCF TTM 27.4m)
Total Stockholder Equity = 190.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.69% (Net Income 20.3m / Total Assets 219.4m)
RoE = 7.20% (Net Income TTM 20.3m / Total Stockholder Equity 281.3m)
RoCE = 7.33% (EBIT 20.6m / Capital Employed (Equity 281.3m + L.T.Debt 100k))
RoIC = 171.8% (NOPAT 15.8m / Invested Capital 9.21m)
WACC = 9.41% (E(312.4m)/V(313.6m) * Re(9.45%) + (debt cost/tax rate unavailable))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 13.48 | Cagr: 0.35%
[DCF] Terminal Value 69.22% ; FCFF base≈41.2m ; Y1≈36.1m ; Y5≈29.2m
[DCF] Fair Price = 7.57 (EV 398.8m - Net Debt -144.3m = Equity 543.1m / Shares 71.7m; r=9.41% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.18 | # QB: 0
Revenue Correlation: 25.41 | Revenue CAGR: 13.98% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.15 | Chg30d=+66.67% | Revisions=-20% | GrowthEPS=-53.1% | GrowthRev=-29.9%
EPS next Year (2027-12-31): EPS=1.05 | Chg30d=-28.57% | Revisions=N/A | GrowthEPS=+600.0% | GrowthRev=+144.4%